High-grade osteosarcoma (HGOS) is the most common malignant tumor of bone. One of the most active drugs for HGOS treatment is doxorubicin, which is invariably included in HGOS chemotherapy protocols together with methotrexate and cisplatin, with the possible addition of ifosfamide. Several studies have shown that HGOS patients may be inherently resistant to doxorubicin or may become unresponsive to this drug during chemotherapeutic treatment. In this review, we will analyze the new and most promising strategies based on doxorubicin regimens for the treatment of HGOS.
Doxorubicin-Resistant Osteosarcoma: novel therapeutic approaches in sight?
RIGANTI, Chiara;
2017-01-01
Abstract
High-grade osteosarcoma (HGOS) is the most common malignant tumor of bone. One of the most active drugs for HGOS treatment is doxorubicin, which is invariably included in HGOS chemotherapy protocols together with methotrexate and cisplatin, with the possible addition of ifosfamide. Several studies have shown that HGOS patients may be inherently resistant to doxorubicin or may become unresponsive to this drug during chemotherapeutic treatment. In this review, we will analyze the new and most promising strategies based on doxorubicin regimens for the treatment of HGOS.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Hattinger, Future Oncology pre-print OA, 2017.pdf
Accesso aperto
Descrizione: Hattinger, preprint open access, 2017
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
157.28 kB
Formato
Adobe PDF
|
157.28 kB | Adobe PDF | Visualizza/Apri |
|
Hattinger, Future Oncology final, 2017.pdf
Accesso riservato
Descrizione: Hattinger, Future Oncology, 2017
Tipo di file:
PDF EDITORIALE
Dimensione
1.1 MB
Formato
Adobe PDF
|
1.1 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
